Intrinsiqs

Is Protalix BioTherapeutics, Inc. overvalued?

Protalix BioTherapeutics, Inc. (PLX) looks fairly valued — trading about 0% above its fair value.

Fairly valued
Current price $3.05 Fair value $3.04
Price
$3.05
Fair value
$3.04
Current P/E
16.8
Normal P/E
16.7
Market cap
$245.7M
Dividend yield
0.0%
Return on equity
30.7%
Sector
Healthcare

See the full interactive analysis →

Fair value compares PLX's current P/E to its own historical "normal" P/E (FAST Graphs-style). Updated 12 Nov 2026.

Related stocks

LLY Eli Lilly and CompanyJNJ Johnson & JohnsonABBV AbbVie Inc.RHHBY Roche Holding AGUNH UnitedHealth Group IncorporatedMRK Merck & Co., Inc.